The involvement of endoplasmic reticulum stress in the suppression of colorectal tumorigenesis by tolfenamic acid

Cancer Prevention Research

Volumn 6, Issue 12, 2013, Pages 1337-1347

  Zhang, Xiaobo ^a,b   Lee, Seong Ho ^c   Min, Kyung Won ^b   McEntee, Michael F ^b   Jeong, Jin Boo ^c   Li, Qingwang ^a   Baek, Seung Joon ^b  

^a NORTHWEST A F UNIVERSITY   (China)

^b UNIVERSITY OF TENNESSEE   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; INITIATION FACTOR 2ALPHA; TOLFENAMIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL GROWTH; COLORECTAL CANCER; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; POLYP; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; UBIQUITINATION; UNFOLDED PROTEIN RESPONSE; UPREGULATION;

ACTIVATING TRANSCRIPTION FACTOR 4; ADENOMATOUS POLYPOSIS COLI PROTEIN; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOTTING, WESTERN; CELL TRANSFORMATION, NEOPLASTIC; COLONIC POLYPS; COLORECTAL NEOPLASMS; CYCLIN D1; EIF-2 KINASE; ENDOPLASMIC RETICULUM STRESS; HUMANS; IMMUNOPRECIPITATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; ORTHO-AMINOBENZOATES; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; UNFOLDED PROTEIN RESPONSE;

EID: 84890527340     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0220     Document Type: Article

References (54)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Kraus S, Arber N. Cancer: do aspirin and other NSAIDs protect against colorectal cancer? Nat Rev Gastroenterol Hepatol 2011;8:125-6.
3. Mann JR, Backlund MG, DuBois RN. Mechanisms of disease: inflammatory mediators and cancer prevention. Nat Clin Pract Oncol 2005; 2:202-10.
4. Wang X, Baek SJ, Eling T. COX inhibitors directly alter gene expression: role in cancer prevention? Cancer Metastasis Rev 2011;30:641-57.
5. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999;5:1418-23.
6. Hansen PE. Tolfenamic acid in acute and prophylactic treatment of migraine: a review. Pharmacol Toxicol 1994;75:81-2.
7. Abdelrahim M, Baker CH, Abbruzzese JL, Safe S. Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst 2006;98:855-68.
8. Papineni S, Chintharlapalli S, Abdelrahim M, Lee SO, Burghardt R, Abudayyeh A, et al. Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. Carcinogenesis 2009;30:1193-201.
9. Liu X, Abdelrahim M, Abudayyeh A, Lei P, Safe S. The nonsteroidal anti-inflammatory drug tolfenamic acid inhibits BT474 and SKBR3 breast cancer cell and tumor growth by repressing erbB2 expression. Mol Cancer Ther 2009;8:1207-17.
10. Colon J, Basha MR, Madero-Visbal R, Konduri S, Baker CH, Herrera LJ, et al. Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice. Invest New Drug 2011;29:41-51.
11. Sankpal UT, Abdelrahim M, Connelly SF, Lee CM, Madero-Visbal R, Colon J, et al. Small molecule tolfenamic acid inhibits PC-3 cell proliferation and invasion in vitro, and tumor growth in orthotopic mouse model for prostate cancer. Prostate 2012;72:1648-58.
12. Kang SU, Shin YS, Hwang HS, Baek SJ, Lee SH, Kim CH. Tolfenamic acid induces apoptosis and growth inhibition in head and neck cancer: involvement of NAG-1 expression. PLoS ONE 2012;7:e34988.
13. Lee SH, Bahn JH, Choi CK, Whitlock NC, English AE, Safe S, et al. ESE-1/EGR-1 pathway plays a role in tolfenamic acid-induced apoptosis in colorectal cancer cells. Mol Cancer Ther 2008;7:3739 -50.
14. Lee SH, Bahn JH, Whitlock NC, Baek SJ. Activating transcription factor 2 (ATF2) controls tolfenamic acid-induced ATF3 expression via MAP kinase pathways. Oncogene 2010;29:5182-92.
15. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 2011;11:558-72.
16. Jirawatnotai S,Hu Y, Michowski W, Elias JE, Becks L, Bienvenu F, et al. A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature 2011;474:230-4.
17. Alao JP. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer 2007;6:24.
18. Brewer JW, Hendershot LM, Sherr CJ, Diehl JA. Mammalian unfolded protein response inhibits cyclin D1 translation and cell-cycle progression. Proc Natl Acad Sci USA 1999;96:8505-10.
19. Szegezdi E, Logue SE, Gorman AM, Samali A. Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep 2006;7:880-5.
20. Tsutsumi S, Gotoh T, Tomisato W, Mima S, Hoshino T, Hwang HJ, et al. Endoplasmic reticulum stress response is involved in nonsteroidal anti-inflammatory drug-induced apoptosis. Cell Death Differ 2004;11:1009-16.
21. Tsutsumi S, Namba T, Tanaka KI, Arai Y, Ishihara T, Aburaya M, et al. Celecoxib upregulates endoplasmic reticulum chaperones that inhibit celecoxib-induced apoptosis in human gastric cells. Oncogene 2006; 25:1018-29.
22. Yamazaki T, Muramoto M, Oe T, Morikawa N, Okitsu O, Nagashima T, et al. Diclofenac, a non-steroidal anti-inflammatory drug, suppresses apoptosis induced by endoplasmic reticulum stresses by inhibiting caspase signaling. Neuropharmacology 2006;50:558-67.
23. Hosoi T, Sasaki M, Baba S, Ozawa K. Effect of pranoprofen on endoplasmic reticulum stress in the primary cultured glial cells. Neurochem Int 2009;54:1-6.
24. Baek SJ, Kim JS, Moore SM, Lee SH, Martinez J, Eling TE. Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein. Mol Pharmacol 2005;67:356-64.
25. Feng Q, Sekula D, Muller R, Freemantle SJ, Dmitrovsky E. Uncovering residues that regulate cyclin D1 proteasomal degradation. Oncogene 2007;26:5098- 106.
26. Wang Y, Shen J, Arenzana N, Tirasophon W, Kaufman RJ, Prywes R. Activation of ATF6 and an ATF6 DNA binding site by the endoplasmic reticulum stress response. J Biol Chem 2000;275:27013-20.
27. Baek SJ, Okazaki R, Lee SH, Martinez J, Kim JS, Yamaguchi K, et al. Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia. Gastroenterology 2006;131:1553-60.
28. Sukhthankar M, Yamaguchi K, Lee SH, McEntee MF, Eling TE, Hara Y, et al. A green tea component suppresses posttranslational expression of basic fibroblast growth factor in colorectal cancer. Gastroenterology 2008;134:1972-80.
29. Wong NACS, Pignatelli M. b-catenin-A linchpin in colorectal carcinogenesis? Am J Pathol 2002;160:389-401.
30. Takada Y, Bhardwaj A, Potdar P, Aggarwal BB. Nonsteroidal antiinflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 2004;23:9247- 58.
31. Geng Y, Yu Q, Sicinska E, Das M, Bronson RT, Sicinski P. Deletion of the p27Kip1 gene restores normal development in cyclin D1-deficient mice. Proc Natl Acad Sci USA 2001;98:194-9.
32. Diehl JA, Zindy F, Sherr CJ. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Gene Dev 1997;11:957-72.
33. Zhang K, Kaufman RJ. Protein folding in the endoplasmic reticulum and the unfolded protein response. Handb Exp Pharmacol 2006;172:69-91.
34. Kim I, Xu W, Reed JC. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov 2008;7:1013-30.
35. Armstrong JL, Flockhart R, Veal GJ, Lovat PE, Redfern CP. Regulation of endoplasmic reticulum stress-induced cell death by ATF4 in neuroectodermal tumor cells. J Biol Chem 2010;285:6091-100.
36. Carracedo A, Gironella M, Lorente M, Garcia S, Guzman M, Velasco G, et al. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res 2006;66:6748- 55.
37. Pathi S, Li X, Safe S. Tolfenamic acid inhibits colon cancer cell and tumor growth and induces degradation of specificity protein (Sp) transcription factors. Mol Carcinog 2013 May 14. [Epub ahead of print].
38. Jeong JB, Yang X, Clark R, Choi J, Baek SJ, Lee SH. A mechanistic study of the proapoptotic effect of tolfenamic acid: involvement of NF-kappaB activation. Carcinogenesis 2013;34:2350-60.
39. Zhang X, Min KW, Liggett J, Baek SJ. Disruption of the transforming growth factor-beta (TGF-beta) pathway by tolfenamic acid via the ERK MAP kinase pathway. Carcinogenesis 2013 July 16. [Epub ahead of print].
40. Eslin D, Sankpal UT, Lee C, Sutphin RM, Maliakal P, Currier E, et al. Tolfenamic acid inhibits neuroblastoma cell proliferation and induces apoptosis: a novel therapeutic agent for neuroblastoma. Mol Carcinog 2013;52:377-86.
41. Basha R, Ingersoll SB, Sankpal UT, Ahmad S, Baker CH, Edwards JR, et al. Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors. Gynecol Oncol 2011;122:163-70.
42. Harding HP, Zhang Y, Ron D. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature 1999; 397:271-4.
43. Hamanaka RB, Bennett BS, Cullinan SB, Diehl JA. PERK and GCN2 contribute to eIF2alpha phosphorylation and cell cycle arrest after activation of the unfolded protein response pathway. Mol Biol Cell 2005;16:5493-501.
44. Romero-Ramirez L, Cao H, Nelson D,Hammond E, Lee AH, Yoshida H, et al. XBP1 is essential for survival under hypoxic conditions and is required for tumor growth. Cancer Res 2004;64:5943-7.
45. Bi M, Naczki C, Koritzinsky M, Fels D, Blais J, Hu N, et al. ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth. EMBO J 2005;24:3470-81.
46. Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci USA 2003;100:9946-51.
47. Nawrocki ST, Carew JS, Dunner K Jr, Boise LH, Chiao PJ, Huang P, et al. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res 2005;65:11510-9.
48. Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Dunner K Jr, Huang P, et al. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res 2005;65:11658-66.
49. Stolfi C, Sarra M, Caruso R, Fantini MC, Fina D, Pellegrini R, et al. Inhibition of colon carcinogenesis by 2-methoxy-5-amino-N-hydroxy-benzamide, a novel derivative of mesalamine. Gastroenterology 2010;138:221-30.
50. Pyrko P, Kardosh A, Liu YT, Soriano N, Xiong W, Chow RH, et al. Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib. Mol Cancer Ther 2007;6:1262-75.
51. Jiang HY, Wek SA, McGrath BC, Lu D, Hai T, Harding HP, et al. Activating transcription factor 3 is integral to the eukaryotic initiation factor 2 kinase stress response. Mol Cell Biol 2004;24:1365-77.
52. Reimertz C,Kogel D, Rami A, Chittenden T, Prehn JH. Gene expression during ER stress-induced apoptosis in neurons: induction of the BH3-only protein Bbc3/PUMAand activation of the mitochondrial apoptosis pathway. J Cell Biol 2003;162:587-97.
53. Zhang T, Nanney LB, Luongo C, Lamps L, Heppner KJ, DuBois RN, et al. Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (Cdk4) in intestinal adenomas from multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients. Cancer Res 1997;57:169-75.
54. Powell SM, Petersen GM, Krush AJ, Booker S, Jen J, Giardiello FM, et al. Molecular diagnosis of familial adenomatous polyposis. N Engl J Med 1993;329:1982-7.